An immunoproteomic approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis.

An immunoproteomic approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis. Pathog Glob Health. 2019 May 17;:1-9 Authors: Rashidi S, Mojtahedi Z, Shahriari B, Kalantar K, Ghalamfarsa G, Mohebali M, Hatam G Abstract Visceral leishmaniasis (VL), the most severe form of leishmaniasis, is caused by Leishmania donovani and Leishmania infantum. The infected dogs with canine visceral leishmaniasis (CVL) are important reservoirs for VL in humans, so the diagnosis, treatment and vaccination of the infected dogs will ultimately decrease the rate of human VL. Proteomics and immunoproteomics techniques have facilitated the introduction of novel drug, vaccine and diagnostic targets. Our immunoproteomic study was conducted to identify new immunoreactive proteins in amastigote form of L. infantum. The strain of L. infantum (MCAN/IR/07/Moheb-gh) was obtained from CVL-infected dogs. J774 macrophage cells were infected with the L. infantum promastigotes. The infected macrophages were ruptured, and pure amastigotes were extracted from the macrophages. After protein extraction, two-dimensional gel electrophoresis was employed for protein separation followed by Western blotting. Western blotting was performed, using symptomatic and asymptomatic sera of the infected dogs with CVL. Thirteen repeatable immunoreactive spots were identified by Matrix-assisted laser desorption/ionization time-...
Source: Pathogens and Global Health - Category: International Medicine & Public Health Tags: Pathog Glob Health Source Type: research

Related Links:

Publication date: Available online 11 June 2019Source: International Journal for Parasitology: Drugs and Drug ResistanceAuthor(s): A.J. Mbekeani, R.S. Jones, M. Bassas Llorens, J. Elliot, C. Regnault, M.P. Barrett, J. Steele, B. Kebede, S.K. Wrigley, L. Evans, P.W. DennyAbstractLeishmaniasis is a Neglected Tropical Disease caused by the insect-vector borne protozoan parasite, Leishmania species. Infection affects millions of the World's poorest, however vaccines are absent and drug therapy limited. Recently, public-private partnerships have developed to identify new modes of controlling leishmaniasis. Most of these collabo...
Source: International Journal for Parasitology: Drugs and Drug Resistance - Category: Parasitology Source Type: research
AbstractWe used TSA as a principal antigen ofLeishmania major with adjuvants. The aim of this research was to assess the efficacy of protein vaccine in the presence of Montanide vis- à-vis chitosan nanoparticle. The expression of recombinant protein was confirmed with SDS (sodium dodecyl sulfate) page and Western blotting. A total of 36 BALB/c mice were divided into six groups (TSA/high chitosan, TSA/low chitosan, TSA/Montanide, high chitosan, low chitosan, and PBS groups) and subcutaneously immunized with 20 mg of vaccine at three time intervals on days 0, 14, and 28. The mice were challenged with parasites 21...
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research
Authors: Ertabaklar H, Çalışkan SÖ, Kolli B, Ertuğ S, Özbilgin A, Malatyalı E, Chang KP Abstract Cutaneous leishmaniasis (CL) is a parasitic disease transmitted by vector sand flies Phlebotomus and Lutzomyia. This disease is characterized by long time non-healing skin lesions, and caused by Leishmania species. CL is the most common infection in Eastern and Southeastern Anatolia in Turkey and L.tropica is known as the main agent of the disease. Number of cases is increasing in our country in time because of malnutrition, migration, travel, low socioeconomic level and ecological changes. For the ...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
In conclusion, this hypothetical protein can be considered as antigenic in TL and VL, as well as a vaccine candidate to be tested in future studies to protect against disease. PMID: 31164242 [PubMed - as supplied by publisher]
Source: Immunobiology - Category: Allergy & Immunology Authors: Tags: Immunobiology Source Type: research
Conclusion: This modified system would be valuable in genome manipulation studies in Leishmania for vaccine research in future. PMID: 31123471 [PubMed]
Source: Iranian Journal of Parasitology - Category: Parasitology Tags: Iran J Parasitol Source Type: research
Conclusion: Immunization with Lip (DOTAP/DOPE/CHO)-SLA+ was not an appropriate strategy to protect mice against leishmaniosis. PMID: 31123470 [PubMed]
Source: Iranian Journal of Parasitology - Category: Parasitology Tags: Iran J Parasitol Source Type: research
Publication date: Available online 20 May 2019Source: Veterinary ParasitologyAuthor(s): Rodolfo Cordeiro Giunchetti, Patricia Silveira, Lucilene Aparecida Resende, Jaqueline Costa Leite, Otoni Alves de Oliveira Melo-Júnior, Marina Luiza Rodrigues Alves, Laís Moreira Costa, Daniel Ferreira Lair, Vinícius Rossi Chaves, Ingrid dos Santos Soares, Ludmila Zanandreis de Mendonça, Mariana Ferreira Lanna, Helen Silva Ribeiro, Ana Alice Maia Gonçalves, Bruno Mendes Roatt, Rodrigo Dian Oliveira Aguiar-Soares, Juliana Vitoriano-Souza, Nádia das Dores Moreira, Fernando Augusto Siqueira Mathias...
Source: Veterinary Parasitology - Category: Veterinary Research Source Type: research
Publication date: Available online 10 May 2019Source: Comparative Immunology, Microbiology and Infectious DiseasesAuthor(s): Abel Martínez-Rodrigo, Alicia Mas, Javier Fernández-Cotrina, Silvia Belinchón-Lorenzo, José A Orden, Pablo Arias, Ricardo de la Fuente, Javier Carrión, Gustavo Domínguez-BernalAbstractHisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of periphe...
Source: Comparative Immunology, Microbiology and Infectious Diseases - Category: Infectious Diseases Source Type: research
Publication date: Available online 10 May 2019Source: Journal of Microbiological MethodsAuthor(s): Juan David Ospina-Villa, Catalina Gómez-Hoyos, Robin Zuluaga-Gallego, Omar Triana-ChávezAbstractThe current therapy for the treatment of leishmaniasis is unsatisfactory because it has multiple side effects, and resistance has been reported among the parasites that cause these diseases. Numerous efforts have been made to develop new candidates for vaccines. In recent years, particles of biodegradable polymers have been proposed as vehicles to transport and protect antigens, proteins, drugs and vaccines. In this w...
Source: Journal of Microbiological Methods - Category: Microbiology Source Type: research
Abstract The generation of an efficacious vaccine that elicits protective CD4+ T cell-mediated immunity has been elusive. The lack of a vaccine against the Leishmania parasite is particularly perplexing as infected individuals acquire life-long immunity to reinfection. Experimental observations suggest that the relationship between immunological memory and protection against Leishmania is not straightforward and that a new paradigm is required to inform vaccine design. These observations include: (i) induction of Th1 memory is a component of protective immunity, but is not sufficient; (ii) memory T cells may be pr...
Source: Trends in Parasitology - Category: Parasitology Authors: Tags: Trends Parasitol Source Type: research
More News: HIV-Leishmania Co-infection | International Medicine & Public Health | Parasitic Diseases | Parasitology | Study | Vaccines